Multidrug　resistance　(MDR)　remains　a　significant　challenge　in　the　field　of　cancer　therapy.　Traditional　chemotherapy　drugs　induce　MDR　in　tumor　cells　during　treatment,　significantly　compromising　treatment　efficacy　and　patient　survival　rates.　Hydrogen　nanobubbles　(NBs)　have　emerged　as　a　promising　therapeutic　technology　due　to　its　excellent　drug　delivery　capabilities　and　biocompatibility,　attracted　considerable　attention　in　recent　years.　In　this　work,　we　established　a　drug-resistant　breast　cancer　cell　model　using　adriamycin　(ADR),　by　treating　it　with　hydrogen　NBs　to　enhance　drug　sensitivity　in　resistant　cells.　This　work　explore　the　mechanism　and　potential　clinical　applications　of　hydrogen　NBs　in　alleviating　multidrug　resistance,　and　providing　a　new　approach　for　collaborative　tumor　therapy　in　breast　cancer.　©　2024　IEEE.